Andrew Schwartz, MD
NPI 1295787000 · Ophthalmology Physician · New York, NY
Enrolled with Medicare as Practitioner - Ophthalmology · source: CMS PECOS Public Provider Enrollment (2026.04.01)
Provider details
- NPI number
- 1295787000
- Entity type
- Individual
- Primary specialty
- Ophthalmology PhysicianAllopathic & Osteopathic Physicians
- Credential
- MD
- Sex
- Male
- Sole proprietor
- No
- License
- PENDING (NY)
Specialties & taxonomies
Allopathic & Osteopathic Physicians
Profile Score
A profile completeness & documented-activity index — NOT a quality, outcomes, or patient-satisfaction rating.
- Registry tenure25% of score
20 yrs in NPPES registry
- Profile completeness25% of score
100% of core fields populated
- Practice footprint15% of score
1 documented practice location
- Medicare service volume (vs. specialty peers)25% of score
6,579 Medicare services, 2024 (ranked within specialty)
- Open Payments transparency10% of score
Has Open Payments disclosures (2024)
Medicare volume is ranked against active providers in the same specialty. Signals a provider has no public data for (e.g. Medicare claims) are left out of the score entirely — never counted as zero — so providers without that data are not penalized. See the full formula and weights in our .
What this provider does (Medicare)
Based on Medicare fee-for-service claims, 2024; not all care is captured.
| Service (HCPCS) | Medicare services | Typical Medicare-allowed (2024) |
|---|---|---|
| Photography of the Retina92250 | 1,368 | $41 |
| Established Patient Complete Exam of Visual System92014 | 880 | $140 |
| Established Patient Problem Focused Exam of Visual System92012 | 511 | $99 |
| Measurement of Corneal Curvature and Depth of Eye92136 | 501 | $34 |
| Exam of Visual Field With Extended Testing92083 | 437 | $71 |
| Established Patient Office Or Other Outpatient Visit With Straightforward Medical Decision Making, If Using Time, 10 Minutes Or More99212 | 437 | $64 |
What this provider prescribes (Medicare Part D)
Top drugs by Medicare Part D claim volume, 2024 · 22 distinct drugs on file.
| Drug | Part D claims (2024) | Beneficiaries |
|---|---|---|
| Latanoprost | 237 | 54 |
| Cyclosporinebrand: Restasis | 179 | 61 |
| Tobramycin/Dexamethasonebrand: Tobramycin-Dexamethasone | 101 | 84 |
| Timolol Maleate | 72 | 17 |
| Lifitegrastbrand: Xiidra | 62 | 16 |
| Cyclosporine | 43 | 18 |
| Erythromycin Basebrand: Erythromycin | 39 | 34 |
Transparency — industry payments
Based on CMS Open Payments, 2024; not all care is captured.
$28,870 across 16 records (Open Payments 2024)
Open Payments discloses payments and transfers of value (meals, travel, consulting, research, royalties) from drug and device makers to providers. This is a transparency signal, not a verdict — such payments are legal and common, and their presence is neither an endorsement nor a criticism. Source: CMS Open Payments, program year 2024.
Practice location
Mailing address
Registry dates
- Enumerated
- 2006-05-17
- Last updated
- 2011-09-29
Source: CMS NPPES Data Dissemination (June 2026). NPI Central is not affiliated with CMS. Data is provided as-is from the public registry.